Skip to main content
Signal8

Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.

Sector: Biotechnology

Industry: Biotechnology

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

OTC:LYRAHealthcare
-84.21%$0.0300
CLOSED
Mkt Cap$337K
EV-
Float1.34M
O/S11.24M
VOL8K sh
$ Vol$244
RVOL1.97×
Inst Own-
SI0.4%
Net Cash/Sh-
EarningsNov 17 · Today
Dilution
Lyra Therapeutics, Inc. logoOTC:LYRAClosed$0.0300-84.21%
FormDescription
    Lyra Therapeutics, Inc. (LYRA) SEC Filings: 10-K, 10-Q, 8-K | Signal8